Last reviewed · How we verify

Placebo (for alirocumab)

Sanofi · Phase 3 active Small molecule

Placebo (for alirocumab) is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Hyperlipidemia.

Placebo does not have a pharmacological effect.

Placebo does not have a pharmacological effect. Used for Hyperlipidemia.

At a glance

Generic namePlacebo (for alirocumab)
SponsorSanofi
ModalitySmall molecule
PhasePhase 3

Mechanism of action

A placebo is a dummy treatment that has no therapeutic effect. It is used as a control in clinical trials to compare the efficacy of active treatments.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo (for alirocumab)

What is Placebo (for alirocumab)?

Placebo (for alirocumab) is a Small molecule drug developed by Sanofi, indicated for Hyperlipidemia.

How does Placebo (for alirocumab) work?

Placebo does not have a pharmacological effect.

What is Placebo (for alirocumab) used for?

Placebo (for alirocumab) is indicated for Hyperlipidemia.

Who makes Placebo (for alirocumab)?

Placebo (for alirocumab) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is Placebo (for alirocumab) in?

Placebo (for alirocumab) is in Phase 3.

What are the side effects of Placebo (for alirocumab)?

Common side effects of Placebo (for alirocumab) include Injection site reaction, Musculoskeletal pain, Fatigue.

Related